他汀降低前列腺癌ADT治疗糖尿病患者痴呆风险
基于台湾全民健康保险数据库的队列研究,纳入1998-2013年新诊断前列腺癌的2型糖尿病患者,经倾向评分匹配后比较他汀使用者与非使用者的痴呆风险。结果显示他汀使用者后续痴呆风险显著降低(HR=0.70,95%CI 0.52-0.94),且他汀使用时长增加与风险降低相关(趋势P=0.002)。
要点
- 接受ADT的前列腺癌合并2型糖尿病患者中,他汀使用与痴呆风险降低相关。
- 他汀使用时长增加与痴呆风险进一步降低相关(趋势P=0.002)。
- 他汀依从性和强度可能增强该获益。
核心结论
- 在接受ADT的前列腺癌合并2型糖尿病患者中,他汀使用与后续痴呆风险显著降低相关。
- 他汀使用时长增加与痴呆风险降低相关,依从性和强度可能增强此获益。
研究设计与样本
- 基于台湾全民健康保险研究数据库的人群基础全国性队列研究。
- 纳入1998至2013年新诊断前列腺癌的2型糖尿病患者,共9855例,其中5427例接受ADT。
- 采用1:1倾向评分匹配的Cox比例风险模型分析,匹配后他汀组和非他汀组各1006例。
主要发现
- 匹配后队列中179例(8.7%)新诊断痴呆。
- 倾向评分匹配分析显示他汀使用者后续痴呆风险显著降低(HR=0.70,95%CI 0.52-0.94),绝对风险降低1%。
- 他汀使用时长增加与痴呆风险显著降低相关(趋势P=0.002)。
临床怎么用
- 对于接受ADT的前列腺癌合并2型糖尿病患者,可考虑他汀使用以降低痴呆风险。
- 他汀使用时长和依从性可能影响痴呆风险降低的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapy (ADT) has been reported to increase the risk of dementia. Statin use decreases the risk of dementia. This study is aimed to investigate the association of statin use and dementia in type 2 diabetic (T2DM) patients receiving ADT. METHODS: Using the National Health Insurance Research Database of Taiwan, we conducted a population-based nationwide cohort study of T2DM patients newly diagnosed with prostate cancer (PCa) between 1998 and 2013. To test statin effects on dementia in T2DM patients receiving ADT, cox proportional hazards models with 1:1 propensity score-matched analysis were used. We divided the study subjects into a statin group and a statin-naive group. The primary outcome was dementia. RESULTS: Of the 9855 selected T2DM patients newly diagnosed with PCa between 1998 and 2013, 5427 patients received ADT for their PCa. After propensity score matching, 1006 statin users and 1006 non-statin users were included in the study cohort, with a mean follow-up period of 3.5 years for the statin group. Among those patients, 179 (8.7%) were newly diagnosed with dementia. A propensity score-matched analysis (hazard ratio = 0.70, 95% confidence interval = 0.52-0.94) demonstrated a significantly decreased risk of subsequent dementia in the statin users with an absolute risk reduction by 1%. A significant decrease in the risk of dementia with increasing statin duration was also demonstrated (P for trend = 0.002). CONCLUSIONS: Statin use in T2DM patients receiving ADT for PCa had decreased risk of dementia, with statin adherence and intensity augmenting this benefit.
引用
- Liu JM, Chen TH, Chuang HC, et al. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 30337635. doi:10.1038/s41391-018-0091-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。